Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, the addition of A-PRF+ to surgical protocols significantly improved bone healing and implant stability when combined with biomaterials, suggesting it as a viable option for patients concerned about using human- and animal-derived biomaterials.

This study concluded that in female pattern hair loss patients, CGF and i-PRF treatments were more effective than PRP in increasing target area hair count, with i-PRF having the lowest adverse event rate.

This article explores the potential of platelet-rich fibrin therapies for androgenetic alopecia and highlights their possible advantages over traditional treatments without reporting new clinical results.

This article discusses the potential role and mechanisms of platelet-rich fibrin therapies in androgenetic alopecia management, exploring their possible benefits over existing treatments but reports no new clinical results.

This study found that certain T cell-associated genes were upregulated in dogs with Vogt-Koyanagi-Harada syndrome and vitiligo, suggesting a shared immunopathogenesis with humans.

This study constructed a model using serum levels of BMP2, CD8A, PRF1, and XCL1 as a non-invasive biomarker to accurately predict recurrence in patients with alopecia areata.

This study demonstrated that the Alopecia Areata Disease Activity Index (ALADIN), a new biomarker, strongly correlates with treatment response in patients using JAK inhibitors for alopecia areata.

In this book, the authors provide an accessible overview of platelet concentrates and their dental applications, highlighting their role in tissue healing and regeneration, and reviewing recent studies on their efficacy in periodontal therapy, implant dentistry, and oral surgery.

This review highlights that autologous platelet concentrates, particularly platelet-rich fibrin, have shown potential to enhance healing and outcomes in both dental and medical applications, including injury recovery and aesthetics.

This study reviews current methods for making and using platelet-rich plasma and fibrin, emphasizing the variability in clinical outcomes due to differences in preparation protocols, and calls for standardized guidelines and large-scale studies for better effectiveness in regenerative medicine.

This narrative review examines the technological advancements and clinical applications of liquid injectable platelet-rich fibrin (i-PRF), discussing its use across regenerative periodontology, sports medicine, and more, as well as its potential as a drug delivery system.

In this study, injectable platelet-rich fibrin (i-PRF) was found to enhance the proliferative, migratory, and hair-inducing abilities of dermal papilla cells more effectively than platelet-rich plasma through the TGF-β/Smad pathway.

This review discusses the use of platelet-rich fibrin (PRF) in musculoskeletal, oral, and maxillofacial surgeries and dermatology, but reports no new clinical results; further trials are needed.

This review highlights PRF's potential as a regenerative medicine tool, detailing its diverse applications in dentistry, orthopedics, and dermatology, but presents no new clinical results.

This study found that TRF1 plays a crucial role in maintaining pluripotency and stem cell compartments, but it is not a suitable in vivo telomere length marker.

This study found that platelet-rich fibrin lysates modulate chemokine expression, reducing inflammation in oral squamous carcinoma cells, but increasing expression in primary oral epithelial cells.

This review discusses the use of platelet-rich fibrin in medical fields, especially dentistry, and reports no new clinical results.

Platelet-rich fibrin is becoming popular for medical and cosmetic uses like hair growth and natural fillers.

This study found that Polycomb repressive complex 1 is crucial for skin development and stem cell specification, influencing gene activity beyond its known repressor functions.

This research overview highlights that although JAK inhibitors show promise as potential treatments for alopecia areata based on recent insights into the disease mechanism, their efficacy has not yet been thoroughly evaluated in a systematic manner.

This study explored the effectiveness of the oral JAK1/2 inhibitor ruxolitinib in treating patients with moderate-to-severe alopecia areata, building on prior success with JAK inhibitors in mice, but results are not reported in this abstract.

This study observed that baricitinib treatment led to significant improvement in a patient's alopecia areata symptoms and suggests further clinical trials to explore its potential as a treatment.

In this study, oral tofacitinib treatment led to significant hair regrowth and changes in skin and blood biomarkers in a patient with alopecia areata.

This review discusses the relationship between aging, chronic inflammation, and immunosuppression, suggesting that these interconnected processes may contribute to tumorigenesis and premature aging, but reports no new experimental results.

This study found distinct gene expression patterns in the blood of alopecia areata patients, suggesting involvement of immune processes and new pathways like Wnt signaling and apoptosis in disease pathogenesis.

This review explores the expression of Perforin by gamma delta T cells in human skin and its role in cytotoxicity but reports no new experimental results.

This study identified KRT82 as a significant Alopecia Areata risk gene, finding that rare damaging variants are linked to elevated immune cell infiltration around hair follicles in affected individuals.

This review discusses the cost-effectiveness and potential benefits of platelet-rich plasma for facial dermal rejuvenation but reports no new clinical results.

This study explored peripheral blood immune dysregulation in alopecia areata through single-cell analyses, identifying systemic changes linked to disease severity and key signaling roles for monocytes, NK cells, and memory T cells, suggesting potential therapeutic targets.

This study identified peripheral myeloid cells as the earliest dysregulated immune cells in PINK1 KO mice with Parkinson’s-like symptoms following intestinal infections, suggesting that PINK1 regulates gut immune functions linked to early Parkinson’s disease mechanisms.